McKinsey & Company to pay $650 million for role in opioid crisis

  • 📰 KPBSnews
  • ⏱ Reading Time:
  • 55 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 63%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

The powerful consulting firm McKinsey will 'accept responsibility' and pay $650 million for helping to fuel the opioid crisis, but executives will once again dodge prosecution.

The global consulting firm McKinsey and Company Friday agreed to pay $650 million to settle a federal probe into its role in helping"turbocharge" sales of the highly addictive opioid painkiller OxyContin for Purdue Pharma, the U.S. Justice Department announced on Friday.the influential consulting company - which often advises governments and powerful corporations around the globe - committed crimes while trying to aggressively boost opioid sales.

That means unless it commits additional wrongdoing linked to opioids, the other executives who led McKinsey during years when it helped drug companies boost prescription opioid sales won't face criminal charges or trial.sent to NPR. The firm also apologized for"the actions of a former partner who deleted documents related to his work for that client.

DOJ officials said the misdemeanor offense involved"knowingly and intentionally conspiring with Purdue and others to aid and abet the misbranding of prescription drugs." Bisch's group, called Relatives Against Purdue Pharma, has staged protests outside DOJ headquarters in Washington, D.C., demanding more accountability for corporate leaders who aggressively promoted and profited from opioid sales.

"Just collecting illicit profits without prosecuting individuals behind the crimes is no real deterrent and it sickens parents like myself," Bisch said., even as their firms paid out billions of dollars in opioid settlements or admitted to criminal acts highly hazardous to the public.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 240. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

McKinsey and Company agrees to pay $650 million to settle federal probe over opioids workCourt papers were filed in Virginia.
La source: sdut - 🏆 5. / 95 Lire la suite »

McKinsey & Company agrees to pay $650 million to settle federal probe over opioids workMcKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia.
La source: wjxt4 - 🏆 246. / 63 Lire la suite »

McKinsey & Company agrees to pay $650 million to settle federal probe over opioids workMcKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia.
La source: KPRC2 - 🏆 80. / 68 Lire la suite »

McKinsey & Company to pay $650 million to settle opioid consulting probe, ex-partner to plead guiltyThe Department of Justice had investigated McKinsey & Company for its consulting work with Purdue Pharma, the prescription opioid maker.
La source: NBCNewYork - 🏆 270. / 63 Lire la suite »

McKinsey & Company agrees to pay $650 million to settle federal probe over opioids workMcKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia.
La source: AP - 🏆 728. / 51 Lire la suite »

McKinsey & Company agrees to $650 million settlement with feds over opioids workConsulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer.
La source: CBSNews - 🏆 87. / 68 Lire la suite »